Lenvatinib Mesylate

CHEMBL2105704 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

523.0 g/mol

LogP

—

Phase

4

The mesylate salt form of lenvatinib, a multi-kinase inhibitor approved for thyroid and liver cancers. It is the pharmaceutical form used in the marketed medication.

分子量

523.0000 g/mol

TPSA

178.00 Å²

治療領域

Ovarian Cancer Pancreatic Cancer Thyroid Cancer Lymphoma Breast Cancer Prostate Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O

InChI

InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)

Molecular Formula

C22H23ClN4O7S

HBD / HBA

4 / 8

回転可能結合数

6

重原子数

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The mesylate salt form of lenvatinib, a multi-kinase inhibitor approved for thyroid and liver cancers. It is the pharmaceutical form used in the marketed medication.

Yes, Lenvatinib Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105704. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11237762. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Lenvatinib Mesylate PillFYIで

構造

クイックデータ

分子式: C22H23ClN4O7S

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.